1
|
Marziali M, Pugliese P, Losardo AA, Ribersani M, Anastasi E, Angeloni A, Pavan A, Gentile G. Efficacy and safety of BNT162b2 mRNA vaccine in a cohort of 90 transfusion dependent thalassemia patients. Transfus Med 2024. [PMID: 38632665 DOI: 10.1111/tme.13038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2023] [Revised: 01/29/2024] [Accepted: 03/20/2024] [Indexed: 04/19/2024]
Affiliation(s)
- M Marziali
- Immunohematology and Transfusion Medicine Unit, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
| | - P Pugliese
- Immunohematology and Transfusion Medicine Unit, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
| | - A A Losardo
- Immunohematology and Transfusion Medicine Unit, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
| | - M Ribersani
- Hematology, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
| | - E Anastasi
- Department of Experimental Medicine, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
| | - A Angeloni
- Department of Experimental Medicine, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
| | - A Pavan
- Immunohematology and Transfusion Medicine Unit, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
| | - G Gentile
- Department of Translational and Precision Medicine, Sapienza Università di Roma, Rome, Italy
| |
Collapse
|
2
|
Anastasi E, Marziali M, Preziosi A, Berardelli E, Losardo AA, Ribersani M, Pugliese P, Farina A, Mancini P, Angeloni A. Humoral immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients. Microbes Infect 2022; 24:104976. [PMID: 35381359 PMCID: PMC8977376 DOI: 10.1016/j.micinf.2022.104976] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 03/11/2022] [Accepted: 03/28/2022] [Indexed: 02/07/2023]
Abstract
One of the most urgent needs worldwide is to vaccinate against SARS-CoV-2 as many people as possible. We evaluated humoral response to Comirnaty vaccine in Thalassemia Major patients (TM). We measured SARS-CoV-2-specific antibodies against Spike protein in 57 TM patients and 58 healthy blood donors (HBD). TM and HBD subjects revealed a homogeneous serological response to the Comirnaty (Mean ± SD; TM = 1917,21 ± 1384,49; HBD = 2039,81 ± 1064,44; p = 0,5884). No statistically significant differences were observed among two groups. Interestingly, we observed in 73.3% of asplenic patients Ab-S titres above 800 BAU, whereas only in 26% of non splenectomized patients showed Ab-S titres above 800 BAU). This differences were statistically significant p < 0.039. Further measurement on other Ab types was needed for better understanding humoral response to Comirnaty.
Collapse
Affiliation(s)
- Emanuela Anastasi
- Department of Experimental Medicine, Policlinico Umberto 1, Sapienza Università di Roma, Roma, Italy.
| | - Marco Marziali
- Immunohematology and Transfusion Medicine Unit, Policlinico Umberto 1, Sapienza Università di Roma, Roma, Italy
| | - Adele Preziosi
- Department of Experimental Medicine, Policlinico Umberto 1, Sapienza Università di Roma, Roma, Italy
| | - Elena Berardelli
- Department of Experimental Medicine, Policlinico Umberto 1, Sapienza Università di Roma, Roma, Italy
| | - Anna Annunziata Losardo
- Immunohematology and Transfusion Medicine Unit, Policlinico Umberto 1, Sapienza Università di Roma, Roma, Italy
| | - Michela Ribersani
- Hematology, Policlinico Umberto 1, Sapienza Università di Roma, Roma, Italy
| | - Pellegrina Pugliese
- Immunohematology and Transfusion Medicine Unit, Policlinico Umberto 1, Sapienza Università di Roma, Roma, Italy
| | - Antonella Farina
- Department of Experimental Medicine, Policlinico Umberto 1, Sapienza Università di Roma, Roma, Italy
| | - Patrizia Mancini
- Department of Experimental Medicine, Policlinico Umberto 1, Sapienza Università di Roma, Roma, Italy
| | - Antonio Angeloni
- Department of Experimental Medicine, Policlinico Umberto 1, Sapienza Università di Roma, Roma, Italy
| |
Collapse
|
3
|
Associations and Disease–Disease Interactions of COVID-19 with Congenital and Genetic Disorders: A Comprehensive Review. Viruses 2022; 14:v14050910. [PMID: 35632654 PMCID: PMC9146233 DOI: 10.3390/v14050910] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 04/23/2022] [Accepted: 04/25/2022] [Indexed: 02/06/2023] Open
Abstract
Since December 2019, the COVID-19 pandemic, which originated in Wuhan, China, has resulted in over six million deaths worldwide. Millions of people who survived this SARS-CoV-2 infection show a number of post-COVID complications. Although, the comorbid conditions and post-COVID complexities are to some extent well reviewed and known, the impact of COVID-19 on pre-existing congenital anomalies and genetic diseases are only documented in isolated case reports and case series, so far. In the present review, we analyzed the PubMed indexed literature published between December 2019 and January 2022 to understand this relationship from various points of view, such as susceptibility, severity and heritability. Based on our knowledge, this is the first comprehensive review on COVID-19 and its associations with various congenital anomalies and genetic diseases. According to reported studies, some congenital disorders present high-risk for developing severe COVID-19 since these disorders already include some comorbidities related to the structure and function of the respiratory and cardiovascular systems, leading to severe pneumonia. Other congenital disorders rather cause psychological burdens to patients and are not considered high-risk for the development of severe COVID-19 infection.
Collapse
|
4
|
Lee JX, Chieng WK, Lau SCD, Tan CE. COVID-19 and Hemoglobinopathies: A Systematic Review of Clinical Presentations, Investigations, and Outcomes. Front Med (Lausanne) 2021; 8:757510. [PMID: 34722593 PMCID: PMC8549676 DOI: 10.3389/fmed.2021.757510] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Accepted: 09/20/2021] [Indexed: 12/29/2022] Open
Abstract
This systematic review aimed to provide an overview of the clinical profile and outcome of COVID-19 infection in patients with hemoglobinopathy. The rate of COVID-19 mortality and its predictors were also identified. A systematic search was conducted in accordance with PRISMA guidelines in five electronic databases (PubMed, Scopus, Web of Science, Embase, WHO COVID-19 database) for articles published between 1st December 2019 to 31st October 2020. All articles with laboratory-confirmed COVID-19 cases with underlying hemoglobinopathy were included. Methodological quality was assessed using the Joanna Briggs Institute (JBI) critical appraisal checklists. Thirty-one articles with data on 246 patients with hemoglobinopathy were included in this review. In general, clinical manifestations of COVID-19 infection among patients with hemoglobinopathy were similar to the general population. Vaso-occlusive crisis occurred in 55.6% of sickle cell disease patients with COVID-19 infection. Mortality from COVID-19 infection among patients with hemoglobinopathy was 6.9%. After adjusting for age, gender, types of hemoglobinopathy and oxygen supplementation, respiratory (adj OR = 89.63, 95% CI 2.514-3195.537, p = 0.014) and cardiovascular (adj OR = 35.20, 95% CI 1.291-959.526, p = 0.035) comorbidities were significant predictors of mortality. Patients with hemoglobinopathy had a higher mortality rate from COVID-19 infection compared to the general population. Those with coexisting cardiovascular or respiratory comorbidities require closer monitoring during the course of illness. More data are needed to allow a better understanding on the clinical impact of COVID-19 infections among patients with hemoglobinopathy. Clinical Trial Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020218200.
Collapse
Affiliation(s)
- Jun Xin Lee
- Department of Pediatrics, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
| | - Wei Keong Chieng
- Department of Family Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
| | - Sie Chong Doris Lau
- Department of Pediatrics, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
| | - Chai Eng Tan
- Department of Family Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
| |
Collapse
|
5
|
Ricchi P, Filosa A. A case of ischemic colitis in a patient with non transfusion dependent thalassemia (NTDT) infected by SARS-COV-2. Pediatr Hematol Oncol 2021; 38:753-756. [PMID: 33970765 DOI: 10.1080/08880018.2021.1922558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Paolo Ricchi
- UOSD Malattie rare del globulo rosso, Azienda Ospedaliera di Rilievo Nazionale "A.Cardarelli", Naples, Italy
| | - Aldo Filosa
- UOSD Malattie rare del globulo rosso, Azienda Ospedaliera di Rilievo Nazionale "A.Cardarelli", Naples, Italy
| |
Collapse
|
6
|
Marziali M, Ribersani M, Losardo AA, Taglietti F, Pugliese P, Micozzi A, Gentile G, Angeloni A. COVID-19 pneumonia and pulmonary microembolism in a patient with B-thalassemia major. Clin Case Rep 2020; 8:3139-3142. [PMID: 33173583 PMCID: PMC7646639 DOI: 10.1002/ccr3.3275] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Accepted: 08/03/2020] [Indexed: 11/26/2022] Open
Abstract
We think that thalassemia is not necessarily a cause of aggravation of the clinical course in COVID‐19; however, certain key factors must be considered, such as the anemic condition, the likely pathogenic role of the virus on hemoglobin, and the hypercoagulable state to prevent any complications.
Collapse
Affiliation(s)
- Marco Marziali
- Hematology Policlinico Umberto 1 Sapienza Università di Roma Roma Italy
| | - Michela Ribersani
- Hematology Policlinico Umberto 1 Sapienza Università di Roma Roma Italy
| | - Anna Annunziata Losardo
- Immunohematology and Transfusion Medicine Unit Policlinico Umberto 1 Sapienza Università di Roma Roma Italy
| | - Fabrizio Taglietti
- Systemic and Immunocompromised Host Infection Unit National Institute for Infectious Diseases "L. Spallanzani" IRCCS Rome Italy
| | - Pellegrina Pugliese
- Immunohematology and Transfusion Medicine Unit Policlinico Umberto 1 Sapienza Università di Roma Roma Italy
| | - Alessandra Micozzi
- Department of Translational and Precision Medicine Sapienza Università di Roma Roma Italy
| | - Giuseppe Gentile
- Department of Translational and Precision Medicine Sapienza Università di Roma Roma Italy
| | - Antonio Angeloni
- Department of Experimental Medicine Sapienza Università di Roma Roma Italy
| |
Collapse
|